Carlos Beltran hopes to begin running next week

1 Comment

Reports last week had Carlos Beltran “not close to returning” from knee surgery, but yesterday the All-Star center fielder told the New York Daily News that he at least plans to begin running by early next week.

Physically, I’m in good shape. I feel strong. When I’m hitting, I feel like I’m hitting good, with power. I’m using my legs, driving the ball. I’m working with a purpose. That’s not the problem. The problem is I couldn’t tolerate some exercises. I’m looking forward to running outside and doing things related to baseball, like in a game. Running is the thing that will dictate everything.

Beltran talking about his hitting sounds encouraging, as does the Daily News‘ description of him “hitting from both sides of the plate and spraying balls all over the outfield” yesterday. Unfortunately the newspaper notes later that the guy he faced “was only pitching underhanded.” So, you know, if the NL ever decides to adopt slow-pitch softball rules, he’ll probably be an MVP candidate.
Within the Daily News article is a picture of the huge knee brace he’s been wearing and Beltran said, “I probably will need to play with it until my knee recuperates from everything.” Brace or not, he’s unlikely to return before June and will need to avoid further setbacks for that to happen.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.